{"id":5732,"date":"2024-06-19T09:05:13","date_gmt":"2024-06-19T14:05:13","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5732"},"modified":"2025-06-27T11:16:41","modified_gmt":"2025-06-27T16:16:41","slug":"nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","title":{"rendered":"Nanoscope Therapeutics participar\u00e1 en Leerink Partners Biopharma Private Company Connect 2024"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">18 de junio de 2024<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (AMD), anunci\u00f3 hoy que la gerencia participar\u00e1 en reuniones individuales con inversionistas en Leerink Partners Biopharma Private Company Connect 2024. retenido virtualmente en\u00a0<span class=\"xn-chron\">25 y 26 de junio de 2024<\/span>.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<\/b><\/p>\n<p>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0la fase de RESTAURACI\u00d3N\u00a0<span class=\"xn-money\">2b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4192527-1&h=3393632503&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D517760235%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT04945772%2525253Fterm%2525253DNanoscope%25252526draw%2525253D2%26a%3DNCT04945772%26a%3DNCT04945772&a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4192527-1&h=2980886663&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D1090222651%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT05417126%2525253Fterm%2525253Dnanoscope%25252526draw%2525253D2%25252526rank%2525253D3%26a%3DNCT05417126%26a%3DNCT05417126&a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la DMAE.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0June 18, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on\u00a0June 25-26, 2024. About Nanoscope Therapeutics Inc. Nanoscope [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5733,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-19T14:05:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:16:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"wordCount\":180,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics participar\u00e1 en el evento Leerink Partners Biopharma Private Company Connect 2024 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-06-19T14:05:13+00:00","article_modified_time":"2025-06-27T16:16:41+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"wordCount":180,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","url":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","name":"Nanoscope Therapeutics participar\u00e1 en el evento Leerink Partners Biopharma Private Company Connect 2024 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5732"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732\/revisions"}],"predecessor-version":[{"id":9043,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732\/revisions\/9043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5733"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}